Epigallocatechin-3-gallate exhibits anti-inflammatory effects in a human interface dermatitis model-implications for...

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Epigallocatechin-3-gallate (EGCG) is known for treating viral warts and possesses anti-inflammatory properties.
• Its therapeutic potential in various dermatoses is under investigation.
• The effect of EGCG on interface dermatitis (ID) has not been previously explored.

Purpose of the Study:

• To investigate the effect of EGCG on a human in vitro model of interface dermatitis (ID).

Main Methods:

• Immunohistochemistry was used to analyze interferon-associated mediators (CXCL10 and MxA) in lesional skin of lichen planus patients and healthy skin.
• Epidermal equivalents and monolayer keratinocytes were stimulated to induce ID-like conditions and treated with EGCG.
• Supernatants were analyzed via ELISA, and cells were assessed for vitality and transcriptomic changes.

Main Results:

• EGCG reduced the intensity of CXCL10 and MxA staining in epidermal equivalents.
• EGCG suppressed CXCL10 secretion by keratinocytes and minimized cytotoxic effects.
• EGCG downregulated key pro-inflammatory cytokines involved in ID perpetuation.

Conclusions:

• EGCG exhibits significant anti-inflammatory effects in a human in vitro model of ID.
• EGCG's ability to suppress disease-perpetuating mediators suggests its potential as a topical therapeutic.
• Further research into EGCG for lichen planus and other autoimmune skin diseases with ID is warranted.